Utilization of the Veterans Affairs Central Cancer Registry to evaluate lung cancer outcomes

Mark Klein, George Scaria, Apar Kishor Ganti

Research output: Contribution to journalReview article

Abstract

Lung cancer is one of the most common and difficult to treat cancers. Veterans are disproportionately affected by lung cancer, as approximately 20% of all cancers diagnosed within the Veteran Affairs health system are lung cancers. Many Veterans have extensive comorbidities, and thus they are often excluded from clinical trials based on this and other eligibility criteria. Thus, while clinical trials are the gold standard to guide treatment decisions, many Veterans’ clinical situations will not align with clinical trial criteria. The Department of Veterans Affairs has established a Central Cancer Registry to aid in evaluation of cancer outcomes and other studies, and data in the registry date back to 1995. This has provided a rich source of data for outcome-based and other research. Here, we highlight studies that utilized the Veterans Affairs Central Cancer Registry to analyze lung cancer outcomes in Veterans treated within the Veterans Affairs health system.

Original languageEnglish (US)
Pages (from-to)321-326
Number of pages6
JournalSeminars in Oncology
Volume46
Issue number4-5
DOIs
StatePublished - Aug 1 2019

Fingerprint

Veterans
Registries
Lung Neoplasms
Veterans Health
Neoplasms
Clinical Trials
Information Storage and Retrieval
Comorbidity
Outcome Assessment (Health Care)
Research

Keywords

  • Cancer registry
  • Lung cancer
  • Outcomes
  • Veterans Affairs

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Utilization of the Veterans Affairs Central Cancer Registry to evaluate lung cancer outcomes. / Klein, Mark; Scaria, George; Ganti, Apar Kishor.

In: Seminars in Oncology, Vol. 46, No. 4-5, 01.08.2019, p. 321-326.

Research output: Contribution to journalReview article

@article{9d9640a8418840fab819d8c769e6ad0a,
title = "Utilization of the Veterans Affairs Central Cancer Registry to evaluate lung cancer outcomes",
abstract = "Lung cancer is one of the most common and difficult to treat cancers. Veterans are disproportionately affected by lung cancer, as approximately 20{\%} of all cancers diagnosed within the Veteran Affairs health system are lung cancers. Many Veterans have extensive comorbidities, and thus they are often excluded from clinical trials based on this and other eligibility criteria. Thus, while clinical trials are the gold standard to guide treatment decisions, many Veterans’ clinical situations will not align with clinical trial criteria. The Department of Veterans Affairs has established a Central Cancer Registry to aid in evaluation of cancer outcomes and other studies, and data in the registry date back to 1995. This has provided a rich source of data for outcome-based and other research. Here, we highlight studies that utilized the Veterans Affairs Central Cancer Registry to analyze lung cancer outcomes in Veterans treated within the Veterans Affairs health system.",
keywords = "Cancer registry, Lung cancer, Outcomes, Veterans Affairs",
author = "Mark Klein and George Scaria and Ganti, {Apar Kishor}",
year = "2019",
month = "8",
day = "1",
doi = "10.1053/j.seminoncol.2019.10.001",
language = "English (US)",
volume = "46",
pages = "321--326",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4-5",

}

TY - JOUR

T1 - Utilization of the Veterans Affairs Central Cancer Registry to evaluate lung cancer outcomes

AU - Klein, Mark

AU - Scaria, George

AU - Ganti, Apar Kishor

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Lung cancer is one of the most common and difficult to treat cancers. Veterans are disproportionately affected by lung cancer, as approximately 20% of all cancers diagnosed within the Veteran Affairs health system are lung cancers. Many Veterans have extensive comorbidities, and thus they are often excluded from clinical trials based on this and other eligibility criteria. Thus, while clinical trials are the gold standard to guide treatment decisions, many Veterans’ clinical situations will not align with clinical trial criteria. The Department of Veterans Affairs has established a Central Cancer Registry to aid in evaluation of cancer outcomes and other studies, and data in the registry date back to 1995. This has provided a rich source of data for outcome-based and other research. Here, we highlight studies that utilized the Veterans Affairs Central Cancer Registry to analyze lung cancer outcomes in Veterans treated within the Veterans Affairs health system.

AB - Lung cancer is one of the most common and difficult to treat cancers. Veterans are disproportionately affected by lung cancer, as approximately 20% of all cancers diagnosed within the Veteran Affairs health system are lung cancers. Many Veterans have extensive comorbidities, and thus they are often excluded from clinical trials based on this and other eligibility criteria. Thus, while clinical trials are the gold standard to guide treatment decisions, many Veterans’ clinical situations will not align with clinical trial criteria. The Department of Veterans Affairs has established a Central Cancer Registry to aid in evaluation of cancer outcomes and other studies, and data in the registry date back to 1995. This has provided a rich source of data for outcome-based and other research. Here, we highlight studies that utilized the Veterans Affairs Central Cancer Registry to analyze lung cancer outcomes in Veterans treated within the Veterans Affairs health system.

KW - Cancer registry

KW - Lung cancer

KW - Outcomes

KW - Veterans Affairs

UR - http://www.scopus.com/inward/record.url?scp=85074510196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074510196&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2019.10.001

DO - 10.1053/j.seminoncol.2019.10.001

M3 - Review article

C2 - 31690464

AN - SCOPUS:85074510196

VL - 46

SP - 321

EP - 326

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4-5

ER -